Drug Research
Strengthening Clinical Evidence Through Female Cohort Representation
The pharmaceutical industry is undergoing a fundamental shift in how it approaches patient diversity within clinical research. For decades, clinical trials often under-represented women, leading to gaps in knowledge regarding drug safety and efficacy for a significant portion of...
Drug Research
Advancing Menopause Treatments Through Hormonal Pathway Research
The pharmaceutical sector is witnessing a renewed focus on the complex biological changes associated with the transition into menopause. Central to this evolution is the depth of hormonal pathway research, which provides the foundation for developing more effective and...
Drug Research
Enhancing Drug Success with Female Cardiovascular Biomarkers
Cardiovascular disease remains a leading cause of mortality among women, yet the mechanisms of disease progression often differ significantly from those observed in men. For many years, the pharmaceutical industry relied on generalized markers of heart health, which occasionally...
Drug Research
Optimizing Autoimmune Selection with Female Immune Biomarkers
Autoimmune diseases affect women at a disproportionately high rate, with nearly 80 percent of all patients being female. Despite this staggering statistic, the underlying biological reasons for this disparity are only recently being understood with the necessary scientific depth....
Drug Research
Dr. Thomas Megerian on Autism, Hope, and the Long Road to Approval
World Pharma Today recently spoke with Dr. Thomas Megerian, a physician who has spent three decades in neurodevelopmental medicine. He serves as Clinical Director of the Thompson Autism and Developmental Center at the Children's Hospital of Orange County and...
Business & Industry
Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal
Roche-owned Genentech has entered into a major collaboration with Earendil Labs to discover and develop bispecific antibodies targeting oncology, in a deal valued at up to $1.5 billion.
Deal Structure and Financial Terms
Under the terms of the agreement, Earendil will...
Business & Industry
AbbVie and Iambic Partner to Accelerate AI Drug Discovery in Immunology, Neuroscience and Oncology
AbbVie and Iambic have entered into a multiyear collaboration focused on AI drug discovery across three major therapeutic areas — immunology, neuroscience, and oncology. The partnership brings together Iambic's molecular superintelligence platform and AbbVie's established drug discovery expertise, with...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read